News & Resources

2013 Press Releases

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Media Contact:
Erika Hackmann
Y&R PR
Phone: 212-303-2305
Email:Erika.Hackmann@yr.com

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/11/13Orexigen Resubmits Contrave New Drug ApplicationPrinter Friendly Version
12/06/13Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior NotesPrinter Friendly Version
12/03/13Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior NotesPrinter Friendly Version
12/02/13Orexigen Therapeutics, Inc. Proposed Offering of $100 Million of Convertible Senior NotesPrinter Friendly Version
11/27/13Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare ConferencePrinter Friendly Version
11/25/13Orexigen Announces Successful Interim Analysis of Contrave Light StudyPrinter Friendly Version
11/24/13Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and WebcastPrinter Friendly Version
11/12/13Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013Printer Friendly Version
11/11/13Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in AtlantaPrinter Friendly Version
11/06/13Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North AmericaPrinter Friendly Version
11/04/13Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare ConferencePrinter Friendly Version
10/03/13Orexigen Therapeutics Submits Contrave Marketing Authorization Application to European Medicines AgencyPrinter Friendly Version
09/06/13Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare ConferencePrinter Friendly Version
08/27/13Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring CommitteePrinter Friendly Version
08/06/13Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013Printer Friendly Version
07/26/13Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and WebcastPrinter Friendly Version
07/03/13Orexigen Therapeutics to Present at the JMP Securities Healthcare ConferencePrinter Friendly Version
06/20/13Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific MeetingPrinter Friendly Version
05/30/13Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare ConferencePrinter Friendly Version
05/17/13Orexigen Therapeutics to Present at the UBS Global Healthcare ConferencePrinter Friendly Version
05/10/13Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care ConferencePrinter Friendly Version
05/08/13Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013Printer Friendly Version
05/02/13Orexigen Therapeutics to Host First Quarter 2013 Financial Results Conference Call and WebcastPrinter Friendly Version
04/25/13Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention PoliciesPrinter Friendly Version
04/22/13Orexigen CEO Michael Narachi Elected to PhRMA Board of DirectorsPrinter Friendly Version
03/13/13Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012Printer Friendly Version
03/07/13Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and WebcastPrinter Friendly Version
02/28/13Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care ConferencePrinter Friendly Version
02/07/13Orexigen Therapeutics to Present at Upcoming Investor ConferencesPrinter Friendly Version
01/07/13Orexigen Therapeutics Announces Progress with FDA on a Faster Path to Resubmission of the Contrave NDAPrinter Friendly Version